Dr. Kellie Murphy
Mount Sinai HospitalView Bio
This pilot study is being conducted to identify whether the addition of progesterone will improve standard care for pregnant women living with HIV. It aims to determine how safe, well-tolerated, easy-to-use, and acceptable progesterone supplementation is for pregnant women living with HIV. This study involves the participants continuing the usual treatment for HIV-positive pregnant women (including anti-retroviral therapy, or ART), and if assigned to the treatment group, taking progesterone.
Standard care for HIV-positive pregnant women involves taking ART medication to prevent mother-to-child transmission and promote maternal health. In Canada, the majority of HIV-positive pregnant women are on ritonavir-boosted, protease inhibitor-based ART. However, multiple studies have shown that this therapy may increase the chances of delivering pre-term (when the baby is born before the 37th week of pregnancy) and having a low birth weight baby (when the baby weighs less than 2.5 kilograms or 5.5 pounds).
Previous research suggests that protease inhibitors may lead to a decrease in progesterone. Progesterone is a very important hormone during pregnancy because it helps maintain a supportive environment for a growing baby. Lower levels of progesterone during pregnancy as a result of protease inhibitor-based ART might contribute to the increased rate of early and low-birth weight deliveries. Supplementing women with progesterone during pregnancy may improve their chances of having a normal weight baby.
In the general population, progesterone supplementation (i.e. Prometrium) is widely used to help prevent a pre-term delivery, especially in pregnant women who have had a pre-term delivery in the past. Progesterone supplementation in pregnancy is well-tolerated and considered safe.
Forty women will participate in this study in different clinics and hospital sites in Ontario. Each will begin the study between weeks 16 and 24 of their pregnancy and will participate up until 4-8 weeks after delivery. Hospital/clinic visits will take place about once every 4 weeks.
Of the 40 participants, 25 will receive progesterone (Group 1) while 15 will receive no treatment and will serve as the comparison group (Group 2). As a result, participants have a greater chance of being placed in Group 1.
For more information on inclusion and exclusion criteria, please refer to clinicaltrials.gov
If you would like more information on this clinical study, please contact Dr. Lena Serghides: (647) 230-7450, email@example.com.
585 University Avenue Toronto, ON M5G 2N2
14 College St. Toronto, ON M5G 1K2
Women's Health Centre 61 Queen Street East, 4th Floor Toronto, ON
600 University Ave Toronto, ON M5G 1X5
2075 Bayview Ave Toronto, ON M4N 3M5
268 Grosvenor Street London, ON N6A 4V2